In case you missed PharmSci360 last year, we are excited to highlight another interesting poster from the conference. There is always really great science presented in the posters at AAPS conferences and we want to make sure that it is shared with the community!
The poster titled "Utilization of Proteomic Surrogates for Early Detection of Unexpected Drug Benefits" was presented at PharmSci360 in Salt Lake City by Jessica Chadwick and colleagues. Summary and highlights of the poster include:
- Utilizing high throughput longitudinal proteomic profiling with SomaScan® technology, found that proteomic "virtual phenotyping" correctly predicted cardiometabolic traits that typically require time-intensive assessments that are not always feasible to perform in large clinical trials.
- Using the EXSCEL, and SUGAR-DM-HF trials as examples to study GLP1-RA, and SGLT2i responses, it was demonstrated that previously validated proteomic surrogates of cardiovascular (CV) events, kidney health, and other cardiometabolic outcomes could have enabled detection of these drug benefits earlier in development in a smaller number of patients, and over a shorter timespan than their respective outcome trials.
- These results highlight the potential clinical utility of protein biosignatures for better targeted outcome trials through patient enrichment and prognostication, and longitudinal monitoring of treatment response.
Simply reply to this post if you have an questions or to start a discussion!
------------------------------
Amanda Hays Ph.D.
Scientific Officer
BioAgilytix
Overland Park KS
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------